{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:58:34Z","timestamp":1793725114427,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cervical cancer remains a significant public health issue in underdeveloped regions like Xinjiang, Western China, where health literacy is low and economic disparities are prominent. While previous studies have focused on preventive measures, there is limited research on the willingness to pay (WTP) for cervical cancer treatments. This study aimed to assess patient preferences and WTP from patient perspective for quality of life improvement, unadjusted life-year extension, and targeted and immunotherapy drugs among cervical cancer patients in Xinjiang.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A face-to-face survey was conducted using the Contingent Valuation Method (CVM) and Discrete Choice Experiment (DCE) to evaluate WTP for cervical cancer treatments. The CVM assessed patients\u2019 WTP for two scenarios: living in perfect health for 5 or 10 years versus unadjusted life-year extension for the same durations. Health related quality of life (HRQoL) was measured using both the EQ-5D-5\u00a0L and EQ-VAS instruments. The DCE evaluated patients\u2019 preferences and WTP for targeted therapy and immunotherapy drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included 106 valid questionnaires (response rate 96.4%), primarily comprising stage III cervical cancer patients (EQ-5D-5\u00a0L 0.89, EQ-VAS 0.80) with characteristics of low income and educational attainment. Key findings revealed: (1) Patients prioritized quality of life improvement over lifespan extension, with WTP\/QALY in the 10-year perfect health scenario exceeding Xinjiang\u2019s 2024 per capita disposable income threshold while other scenarios remained below this value, and WTP\/QALY being significantly higher in the 10-year scenario compared to the 5-year scenario; (2) Medication preference analysis demonstrated that quality of life improvement, cost, and incidence of adverse reactions were key decision-making factors, whereas survival extension held relatively lower importance. WTP valuations exhibited significant attribute-specific variations, with the highest WTP corresponding to quality of life improvement attributes and the lowest to survival extension attributes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Cervical cancer patients in Xinjiang prioritize quality of life improvement over lifespan extension, with their preferences and WTP being influenced by treatment-related factors, disease characteristics, and socioeconomic background. Therefore, when formulating reimbursement policies and resource allocation strategies, priority should be given to interventions that can significantly improve quality of life, while implementing differentiated support policies for patient populations with varying socioeconomic statuses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00938-6","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:05:15Z","timestamp":1755792315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1933-7258","authenticated-orcid":false,"given":"Lina","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8946","authenticated-orcid":false,"given":"Yubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"1","key":"938_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al (2024) Cancer incidence and mortality in china, 2022. J Natl Cancer Cent 4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"938_CR2","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B et al (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Global Health 11(2):e197\u2013e206. https:\/\/doi.org\/10.1016\/S2214-109X(22)00501-0","journal-title":"Lancet Global Health"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","volume":"13","author":"CA Burmeister","year":"2022","unstructured":"Burmeister CA, Khan SF, Sch\u00e4fer G, Mbatani N, Adams T, Moodley J et al (2022) Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res 13:200238. https:\/\/doi.org\/10.1016\/j.tvr.2022.200238","journal-title":"Tumour Virus Res"},{"issue":"6","key":"938_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.21147\/j.issn.1000-9604.2023.06.11","volume":"35","author":"H Chen","year":"2023","unstructured":"Chen H, Zhao X, Hu S, You T, Xia C, Gao M et al (2023) Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in china: a nationwide multicenter cross-sectional study. Chin J Cancer Res 35(6):675\u2013685. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2023.06.11","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"938_CR5","doi-asserted-by":"publisher","first-page":"e0232129","DOI":"10.1371\/journal.pone.0232129","volume":"15","author":"Q Wu","year":"2020","unstructured":"Wu Q, Jia M, Chen H, Zhang S, Liu Y, Prem K et al (2020) The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan province, china: A retrospective case series study. PLoS ONE 15(5):e0232129. https:\/\/doi.org\/10.1371\/journal.pone.0232129","journal-title":"PLoS ONE"},{"issue":"5","key":"938_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","volume":"19","author":"L Vallejo-Torres","year":"2016","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Castilla I, Valc\u00e1rcel-Nazco C, Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R et al (2016) On the Estimation of the Cost-Effectiveness threshold: why, what, how? Value Health 19(5):558\u2013566. https:\/\/doi.org\/10.1016\/j.jval.2016.02.020","journal-title":"Value Health"},{"key":"938_CR7","doi-asserted-by":"publisher","unstructured":"Xu L, Chen M, Angell B, Jiang Y, Howard K, Jan S et al (2024) Establishing cost-effectiveness threshold in china: a community survey of willingness to pay for a healthylife year. BMJ Glob Health 9(1). https:\/\/doi.org\/10.1136\/bmjgh-2023-013070","DOI":"10.1136\/bmjgh-2023-013070"},{"issue":"1","key":"938_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12962-023-00487-z","volume":"21","author":"Q Peng","year":"2023","unstructured":"Peng Q, Yin Y, Liang M, Zhao M, Shao T, Tang Y et al (2023) Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method. Cost Eff Resour Alloc 21(1):80. https:\/\/doi.org\/10.1186\/s12962-023-00487-z","journal-title":"Cost Eff Resour Alloc"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"104695","DOI":"10.1016\/j.ijnurstu.2024.104695","volume":"152","author":"S Liu","year":"2024","unstructured":"Liu S, Xiang Y, Gu Y, Chen N, Fu P, Wei Y et al (2024) Patient preferences and willingness to pay for central venous access devices in breast cancer: a multicenter discrete choice experiment. Int J Nurs Stud 152:104695. https:\/\/doi.org\/10.1016\/j.ijnurstu.2024.104695","journal-title":"Int J Nurs Stud"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"469580211024894","DOI":"10.1177\/00469580211024894","volume":"58","author":"M Chaikumbung","year":"2021","unstructured":"Chaikumbung M (2021) Democracy, culture and cancer patients\u2019 willingness to pay for healthcare services: a meta-analysis. Inquiry 58:469580211024894. https:\/\/doi.org\/10.1177\/00469580211024894","journal-title":"Inquiry"},{"issue":"1","key":"938_CR11","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J (2020) Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy 8(1):1717030. https:\/\/doi.org\/10.1080\/20016689.2020.1717030","journal-title":"J Mark Access Health Policy"},{"issue":"8","key":"938_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1021\/es990728j","volume":"34","author":"RT Carson","year":"2000","unstructured":"Carson RT (2000) Contingent valuation: a user\u2019s guide. Environ Sci Technol 34(8):1413\u20131418. https:\/\/doi.org\/10.1021\/es990728j","journal-title":"Environ Sci Technol"},{"issue":"2","key":"938_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM (2019) Discrete choice experiments in health economics: past, present and future. PharmacoEconomics 37(2):201\u2013226. https:\/\/doi.org\/10.1007\/s40273-018-0734-2","journal-title":"PharmacoEconomics"},{"issue":"4","key":"938_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1017\/S0266462315000409","volume":"31","author":"S Thongprasert","year":"2015","unstructured":"Thongprasert S, Crawford B, Sakulbumrungsil R, Chaiyakunapruk N, Petcharapiruch S, Leartsakulpanitch J et al (2015) Willingness to pay for lung cancer treatment: patient versus general public values. Int J Technol Assess Health Care 31(4):264\u2013270. https:\/\/doi.org\/10.1017\/S0266462315000409","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"938_CR15","doi-asserted-by":"publisher","first-page":"e19379","DOI":"10.1097\/MD.0000000000019379","volume":"99","author":"TV Ha","year":"2020","unstructured":"Ha TV, Hoang MV, Vu MQ, Hoang NT, Khuong LQ, Vu AN et al (2020) Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet nam, 2018. Medicine 99(9):e19379. https:\/\/doi.org\/10.1097\/MD.0000000000019379","journal-title":"Medicine"},{"issue":"6","key":"938_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1524-4733.2010.00743.x","volume":"13","author":"HC Lang","year":"2010","unstructured":"Lang HC (2010) Willingness to pay for lung cancer treatment. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 13(6):743\u2013749. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00743.x","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"1062830","DOI":"10.3389\/fpsyg.2023.1062830","volume":"14","author":"S Oliveri","year":"2023","unstructured":"Oliveri S, Lanzoni L, Veldwijk J, de Wit GA, Petrocchi S, Janssens R et al (2023) Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives. Front Psychol 14:1062830. https:\/\/doi.org\/10.3389\/fpsyg.2023.1062830","journal-title":"Front Psychol"},{"issue":"3","key":"938_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jjco\/hyaa241","volume":"51","author":"T Iwatani","year":"2021","unstructured":"Iwatani T, Hara F, Shien T, Sasaki K, Katayama H, Fukuda H et al (2021) Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A). Jpn J Clin Oncol 51(3):498\u2013503. https:\/\/doi.org\/10.1093\/jjco\/hyaa241","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"938_CR19","doi-asserted-by":"publisher","first-page":"e0300631","DOI":"10.1371\/journal.pone.0300631","volume":"19","author":"T Demeke","year":"2024","unstructured":"Demeke T, Hailemariam D, Santos P, Seife E, Addissie A, Sven Kroeber E et al (2024) Willingness and ability to pay for breast cancer treatment among patients from addis ababa, ethiopia: a cross-sectional study. PLoS ONE 19(3):e0300631. https:\/\/doi.org\/10.1371\/journal.pone.0300631","journal-title":"PLoS ONE"},{"issue":"2","key":"938_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1524-4733.2008.00417.x","volume":"12","author":"K Howard","year":"2009","unstructured":"Howard K, Salkeld G (2009) Does attribute framing in discrete choice experiments influence willingness to pay? Results from a discrete choice experiment in screening for colorectal cancer. Value Health 12(2):354\u2013363. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00417.x","journal-title":"Value Health"},{"issue":"11","key":"938_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2165\/00019053-200220110-00006","volume":"20","author":"M Aristides","year":"2002","unstructured":"Aristides M, Chen J, Schulz M, Williamson E, Clarke S, Grant K (2002) Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. PharmacoEconomics 20(11):775\u2013784. https:\/\/doi.org\/10.2165\/00019053-200220110-00006","journal-title":"PharmacoEconomics"},{"issue":"10","key":"938_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/hec.1786","volume":"21","author":"HC Lang","year":"2012","unstructured":"Lang HC, Chang K, Ying YH (2012) Quality of life, treatments, and patients\u2019 willingness to pay for a complete remission of cervical cancer in Taiwan. Health Econ 21(10):1217\u20131233. https:\/\/doi.org\/10.1002\/hec.1786","journal-title":"Health Econ"},{"issue":"1","key":"938_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12905-018-0512-5","volume":"18","author":"G Abulizi","year":"2018","unstructured":"Abulizi G, Abulimiti T, Li H, Abuduxikuer G, Mijiti P, Zhang SQ et al (2018) Knowledge of cervical cancer and pap smear among Uyghur women from xinjiang, China. BMC Womens Health 18(1):21. https:\/\/doi.org\/10.1186\/s12905-018-0512-5","journal-title":"BMC Womens Health"},{"issue":"15","key":"938_CR24","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1097\/CM9.0000000000001441","volume":"134","author":"Y Wang","year":"2021","unstructured":"Wang Y, Cai YB, James W, Zhou JL, Rezhake R, Zhang Q (2021) Human papillomavirus distribution and cervical cancer epidemiological characteristics in rural population of xinjiang, China. Chin Med J 134(15):1838\u20131844. https:\/\/doi.org\/10.1097\/CM9.0000000000001441","journal-title":"Chin Med J"},{"issue":"8","key":"938_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J (2008) Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. PharmacoEconomics 26(8):661\u2013677. https:\/\/doi.org\/10.2165\/00019053-200826080-00004","journal-title":"PharmacoEconomics"},{"issue":"1","key":"938_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12962-021-00298-0","volume":"19","author":"Z Ye","year":"2021","unstructured":"Ye Z, Liu F, Ma J, Zhou Z, Wang C, Sun L (2021) Comparing the monetary value of a quality-adjusted life year from the payment card and the open-ended format. Cost Eff Resour Alloc 19(1):45. https:\/\/doi.org\/10.1186\/s12962-021-00298-0","journal-title":"Cost Eff Resour Alloc"},{"key":"938_CR27","unstructured":"National Bureau of Statistics of China, Statistical communiqu\u00c9 of the people\u2019s Republic of China on the 2023 National Economic and Social development (2024). https:\/\/www.stats.gov.cn\/english\/PressRelease\/202402\/t20240228_1947918.html#:~:text=The%20per%20capita%20GDP%20in%202023%20was%2089%2C358,up%20by%205.7%20percent%20over%20the%20previous%20year. Accessed 30 August 2024"},{"issue":"4","key":"938_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K (2017) Estimating an EQ-5D-5L value set for China. Value Health 20(4):662\u2013669. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016","journal-title":"Value Health"},{"issue":"1","key":"938_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12955-024-02272-9","volume":"22","author":"C Shaw","year":"2024","unstructured":"Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW (2024) A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment. Health Qual Life Outcomes 22(1):63. https:\/\/doi.org\/10.1186\/s12955-024-02272-9","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"938_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S (2023) Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. PharmacoEconomics 41(1):43\u201357. https:\/\/doi.org\/10.1007\/s40273-022-01198-8","journal-title":"PharmacoEconomics"},{"issue":"6","key":"938_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R et al (2021) A systematic review of discrete choice experiments in oncology treatments. Patient 14(6):775\u2013790. https:\/\/doi.org\/10.1007\/s40271-021-00520-4","journal-title":"Patient"},{"key":"938_CR32","doi-asserted-by":"publisher","first-page":"102225","DOI":"10.1016\/j.ctrv.2021.102225","volume":"98","author":"FJ Crowley","year":"2021","unstructured":"Crowley FJ, O\u2019Cearbhaill RE, Collins DC (2021) Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer. Cancer Treat Rev 98:102225. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102225","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"938_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11912-018-0680-3","volume":"20","author":"G Marquina","year":"2018","unstructured":"Marquina G, Manzano A, Casado A (2018) Targeted agents in cervical cancer: beyond bevacizumab. Curr Oncol Rep 20(5):40. https:\/\/doi.org\/10.1007\/s11912-018-0680-3","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"938_CR34","doi-asserted-by":"publisher","first-page":"e000462","DOI":"10.1136\/esmoopen-2018-000462","volume":"3","author":"C Vora","year":"2018","unstructured":"Vora C, Gupta S (2018) Targeted therapy in cervical cancer. ESMO Open 3(1):e000462. https:\/\/doi.org\/10.1136\/esmoopen-2018-000462","journal-title":"ESMO Open"},{"key":"938_CR35","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.2147\/ott.S264312","volume":"13","author":"L Guo","year":"2020","unstructured":"Guo L, Hua K (2020) Cervical cancer: emerging immune landscape and treatment. Onco Targets Ther 13:8037\u20138047. https:\/\/doi.org\/10.2147\/ott.S264312","journal-title":"Onco Targets Ther"},{"issue":"3","key":"938_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/ijgc-2021-002492","volume":"32","author":"MV Sherer","year":"2022","unstructured":"Sherer MV, Kotha NV, Williamson C, Mayadev J (2022) Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Gynecol Cancer 32(3):281\u2013287. https:\/\/doi.org\/10.1136\/ijgc-2021-002492","journal-title":"Int J Gynecol Cancer"},{"key":"938_CR37","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"B Orme","year":"2019","unstructured":"Orme B (2019) Getting started with conjoint analysis: strategies for product design and pricing research, 4th edn. Research Publishers LLC, Madison, WI","edition":"4"},{"key":"938_CR38","unstructured":"the National Bureau of Statistics (2024) Statistical Communiqu\u00e9 on the National Economic and Social Development of Xinjiang Uygur Autonomous Region in 2023. https:\/\/www.xinjiang.gov.cn\/xinjiang\/tjgb\/202404\/78f1b33dcaa94a9b83a8d291d0ff0461.shtml. Accessed 11 September 2024"},{"key":"938_CR39","doi-asserted-by":"publisher","first-page":"115909","DOI":"10.1016\/j.socscimed.2023.115909","volume":"326","author":"B Fischer","year":"2023","unstructured":"Fischer B, Telser H, Zweifel P, von Wyl V, Beck K, Weber A (2023) The value of a QALY towards the end of life and its determinants: experimental evidence. Soc Sci Med 326:115909. https:\/\/doi.org\/10.1016\/j.socscimed.2023.115909","journal-title":"Soc Sci Med"},{"issue":"1","key":"938_CR40","doi-asserted-by":"publisher","first-page":"e013070","DOI":"10.1136\/bmjgh-2023-013070","volume":"9","author":"L Xu","year":"2024","unstructured":"Xu L, Chen M, Angell B, Jiang Y, Howard K, Jan S et al (2024) Establishing cost-effectiveness threshold in china: a community survey of willingness to pay for a healthylife year. BMJ Global Health 9(1):e013070. https:\/\/doi.org\/10.1136\/bmjgh-2023-013070","journal-title":"BMJ Global Health"},{"issue":"1","key":"938_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12962-023-00442-y","volume":"21","author":"L Huang","year":"2023","unstructured":"Huang L, Peng X, Sun L, Zhang D (2023) Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China. Cost Eff Resour Alloc 21(1):37. https:\/\/doi.org\/10.1186\/s12962-023-00442-y","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"938_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2023.2262141","volume":"24","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Yang Y, Wu W, Dong H (2024) Willingness to pay for cancer prevention versus treatment in china: implications for cost-effectiveness threshold. Expert Rev PharmacoEcon Outcomes Res 24(1):155\u2013160. https:\/\/doi.org\/10.1080\/14737167.2023.2262141","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"4","key":"938_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","volume":"23","author":"D Cai","year":"2022","unstructured":"Cai D, Shi S, Jiang S, Si L, Wu J, Jiang Y (2022) Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ 23(4):607\u2013615. https:\/\/doi.org\/10.1007\/s10198-021-01384-z","journal-title":"Eur J Health Econ"},{"issue":"6","key":"938_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40258-022-00750-z","volume":"20","author":"Z Ye","year":"2022","unstructured":"Ye Z, Abduhilil R, Huang J, Sun L (2022) Willingness to pay for one additional quality adjusted life year: a population based survey from China. Appl Health Econ Health Policy 20(6):893\u2013904. https:\/\/doi.org\/10.1007\/s40258-022-00750-z","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"938_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jval.2020.11.015","volume":"24","author":"J Bovenberg","year":"2021","unstructured":"Bovenberg J, Penton H, Buyukkaramikli N (2021) 10 years of End-of-Life criteria in the united Kingdom. Value Health 24(5):691\u2013698. https:\/\/doi.org\/10.1016\/j.jval.2020.11.015","journal-title":"Value Health"},{"key":"938_CR46","unstructured":"Xinjiang Uygur Autonomous Region Bureau of Statistics (2025) Statistical Communiqu\u00e9 on the National Economic and Social Development of Xinjiang Uygur Autonomous Region in 2024. https:\/\/www.xinjiang.gov.cn\/xinjiang\/tjgb\/202503\/f0578f74e4e04369af0ee82566586397.shtml. Accessed 13 May 2025"},{"issue":"2","key":"938_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10198-021-01364-3","volume":"23","author":"CRC Kouakou","year":"2022","unstructured":"Kouakou CRC, Poder TG (2022) Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. Eur J Health Econ 23(2):277\u2013299. https:\/\/doi.org\/10.1007\/s10198-021-01364-3","journal-title":"Eur J Health Econ"},{"issue":"3","key":"938_CR48","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11002-012-9177-2","volume":"23","author":"C Schlereth","year":"2012","unstructured":"Schlereth C, Eckert C, Skiera B (2012) Using discrete choice experiments to estimate willingness-to-pay intervals. Mark Lett 23(3):761\u2013776. https:\/\/doi.org\/10.1007\/s11002-012-9177-2","journal-title":"Mark Lett"},{"issue":"6","key":"938_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10198-017-0929-z","volume":"19","author":"B Sund","year":"2018","unstructured":"Sund B, Svensson M (2018) Estimating a constant WTP for a QALY-a mission impossible? Eur J Health Econ 19(6):871\u2013880. https:\/\/doi.org\/10.1007\/s10198-017-0929-z","journal-title":"Eur J Health Econ"},{"issue":"10","key":"938_CR50","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jval.2022.05.003","volume":"25","author":"M Zhang","year":"2022","unstructured":"Zhang M, He X, Wu J, Wang X, Jiang Q, Xie F (2022) How do treatment preferences of patients with cancer compare with those of oncologists and family members? Evidence from a discrete choice experiment in China. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 25(10):1768\u20131777. https:\/\/doi.org\/10.1016\/j.jval.2022.05.003","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"4","key":"938_CR51","doi-asserted-by":"publisher","first-page":"e0122760","DOI":"10.1371\/journal.pone.0122760","volume":"10","author":"K Nimdet","year":"2015","unstructured":"Nimdet K, Chaiyakunapruk N, Vichansavakul K, Ngorsuraches S (2015) A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS ONE 10(4):e0122760. https:\/\/doi.org\/10.1371\/journal.pone.0122760","journal-title":"PLoS ONE"},{"issue":"1","key":"938_CR52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, He X, Wu J, Xie F (2023) Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer 23(1):1126. https:\/\/doi.org\/10.1186\/s12885-023-11598-4","journal-title":"BMC Cancer"},{"issue":"7","key":"938_CR53","doi-asserted-by":"publisher","first-page":"e0219455","DOI":"10.1371\/journal.pone.0219455","volume":"14","author":"Y Cho","year":"2019","unstructured":"Cho Y, Lee JK, Kim DH, Park JH, Choi M, Kim HJ et al (2019) Factors associated with quality of life in patients with depression: a nationwide population-based study. PLoS ONE 14(7):e0219455. https:\/\/doi.org\/10.1371\/journal.pone.0219455","journal-title":"PLoS ONE"},{"issue":"1","key":"938_CR54","doi-asserted-by":"publisher","first-page":"13562","DOI":"10.1038\/s41598-022-17942-1","volume":"12","author":"K Kucnerowicz","year":"2022","unstructured":"Kucnerowicz K, Pietrzak A, Cholewi\u0144ski W, Martenka P, Marsza\u0142ek A, Burchardt E et al (2022) The quality-adjusted life-years in the oncological patients\u2019 health-related quality of life. Sci Rep 12(1):13562. https:\/\/doi.org\/10.1038\/s41598-022-17942-1","journal-title":"Sci Rep"},{"issue":"4","key":"938_CR55","doi-asserted-by":"publisher","first-page":"e228788","DOI":"10.1001\/jamanetworkopen.2022.8788","volume":"5","author":"A Leng","year":"2022","unstructured":"Leng A, Maitland E, Wang S, Nicholas S, Lan K, Wang J (2022) Preferences for End-of-Life care among patients with terminal cancer in China. JAMA Netw Open 5(4):e228788. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8788","journal-title":"JAMA Netw Open"},{"issue":"6","key":"938_CR56","doi-asserted-by":"publisher","first-page":"e072469","DOI":"10.1136\/bmjopen-2023-072469","volume":"13","author":"Z Feng","year":"2023","unstructured":"Feng Z, Meng J, Sun Y, Xie T, Lu W, Wang G et al (2023) Assessment of patients\u2019 preferences for new anticancer drugs in china: a best-worst discrete choice experiment on three common cancer types. BMJ Open 13(6):e072469. https:\/\/doi.org\/10.1136\/bmjopen-2023-072469","journal-title":"BMJ Open"},{"issue":"12","key":"938_CR57","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jval.2023.08.009","volume":"26","author":"ASJ Yong","year":"2023","unstructured":"Yong ASJ, Lim KK, Fox-Rushby J, Ismail F, Hamzah E, Cheong MWL et al (2023) A longitudinal evaluation of the preferences of patients with advanced cancer for quality of life and survival in malaysia: a discrete choice experiment. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 26(12):1772\u20131781. https:\/\/doi.org\/10.1016\/j.jval.2023.08.009","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"3","key":"938_CR58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11136-023-03562-3","volume":"33","author":"Y Yin","year":"2024","unstructured":"Yin Y, Peng Q, Ma L, Dong Y, Sun Y, Xu S et al (2024) QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment. Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation 33(3):753\u2013765. https:\/\/doi.org\/10.1007\/s11136-023-03562-3","journal-title":"Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation"},{"key":"938_CR59","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/ppa.S302394","volume":"15","author":"I Meirelles","year":"2021","unstructured":"Meirelles I, Magliano C (2021) Stated preferences in Non-Small-Cell lung cancer: A discrete choice experiment. Patient Prefer Adherence 15:911\u2013917. https:\/\/doi.org\/10.2147\/ppa.S302394","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"938_CR60","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/jnci\/djad138","volume":"115","author":"MD Brundage","year":"2023","unstructured":"Brundage MD, Booth CM, Eisenhauer EA, Galica J, Kankesan J, Karim S et al (2023) Patients\u2019 attitudes and preferences toward delayed disease progression in the absence of improved survival. J Natl Cancer Inst 115(12):1526\u20131534. https:\/\/doi.org\/10.1093\/jnci\/djad138","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"938_CR61","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/journalofethics.2015.17.11.stas1-1511","volume":"17","author":"V Arora","year":"2015","unstructured":"Arora V, Moriates C, Shah N (2015) The challenge of Understanding health care costs and charges. AMA J Ethics 17(11):1046\u20131052. https:\/\/doi.org\/10.1001\/journalofethics.2015.17.11.stas1-1511","journal-title":"AMA J Ethics"},{"issue":"4","key":"938_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00199-017-1096-2","volume":"67","author":"KM Werner","year":"2019","unstructured":"Werner KM, Zank H (2019) A revealed reference point for prospect theory. Econ Theor 67(4):731\u2013773. https:\/\/doi.org\/10.1007\/s00199-017-1096-2","journal-title":"Econ Theor"},{"issue":"3","key":"938_CR63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10198-018-1008-9","volume":"20","author":"SA Lipman","year":"2019","unstructured":"Lipman SA, Brouwer WBF, Attema AE (2019) A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health States. Eur J Health Econ 20(3):419\u2013426. https:\/\/doi.org\/10.1007\/s10198-018-1008-9","journal-title":"Eur J Health Econ"},{"issue":"1","key":"938_CR64","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12889-024-18338-8","volume":"24","author":"Y Lyu","year":"2024","unstructured":"Lyu Y, Xu Q, Liu J (2024) Exploring the medical decision-making patterns and influencing factors among the general Chinese public: a binary logistic regression analysis. BMC Public Health 24(1):887. https:\/\/doi.org\/10.1186\/s12889-024-18338-8","journal-title":"BMC Public Health"},{"key":"938_CR65","unstructured":"Center for Drug, Evaluation CDA (2024) Guidelines for the Application of Patient-Reported Outcomes in Drug Clinical Development (Trial). https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c2f79c22e8678241b030c71523eb300c. Accessed May 7 2025"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00938-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00938-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00938-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:05:17Z","timestamp":1755792317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00938-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00938-6","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Scientific Research Ethics Committee of First Affiliated Hospital of Xinjiang Medical University reviewed and approved the research protocol, approval reference number K202401-01. As this study did not involve any interventional procedures, verbal informed consent was obtained from all participants before their inclusion in the study. Participants were provided detailed information about the study\u2019s purpose, procedures, potential risks, and benefits. They were assured that their participation was voluntary, that their responses would be kept confidential, and that their data would be anonymized. Participants were also informed that they could withdraw from the study at any time without any impact on their medical treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its submission for publication. Informed consent was obtained from all participants involved in this study. The data have been anonymized to ensure confidentiality, and no personally identifiable information is included. The consent forms are retained by the authors and can be provided upon request by the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors (Lina ZHU, Yan WANG, Shangjie YANG, Qianhui LI, Jie WANG, Jun ZHAO, Jianhua WANG, Yubo WANG) have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}